Week In Review: Suzhou's Adagene Raises $140 Million In US IPO To Develop Oncology Drugs
February 13, 2021 at 12:37 PM EST
Adagene, a Suzhou immunoncology biopharma, completed a $140 million NASDAQ IPO and climbed 56% higher in open market trading. Adagene has a market capitalization of about $1 billion.
